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Abstract  
Phenylalanine hydroxylase (PAH) deficiency, colloquially known as phenylketonuria 
(PKU), is among the most common inborn errors of metabolism and in the past decade 
has become a target for the development of novel therapeutics such as gene therapy. 
PAH deficient mouse models have been key to new treatment development, but all prior 
existing models natively express liver PAH polypeptide as inactive or partially active 
PAH monomers, which complicates the experimental assessment of protein expression 
following therapeutic gene, mRNA, protein, or cell transfer. The mutant PAH monomers 
are able to form hetero-tetramers with and inhibit the overall holoenzyme activity of wild 
type PAH monomers produced from a therapeutic vector. Preclinical therapeutic studies 
would benefit from a PKU model that completely lacks both PAH activity and protein 
expression in liver. In this study, we employed CRISPR/Cas9-mediated gene editing in 
fertilized mouse embryos to generate a novel mouse model that lacks exon 1 of the Pah 
gene. Mice that are homozygous for the Pah exon 1 deletion are viable, severely 
hyperphenylalaninemic, accurately replicate phenotypic features of untreated human 
classical PKU and lack any detectable liver PAH activity or protein. This model of 
classical PKU is ideal for further development of gene and cell biologics to treat PKU.  
 










1. Introduction  
 
Phenylketonuria (PKU) (OMIM # 261600) is among the most well-studied inborn errors 
of metabolism. PKU is most commonly caused by phenylalanine hydroxylase (PAH, EC 
1.14.16.1) deficiency as the result of inherited PAH mutations, but can also be caused 
by mutations in the DNAJC12 gene, one of the co-chaperones required for proper PAH 
folding and degradation [1]. PAH deficiency results in hyperphenylalaninemia (HPA) and 
irreversible neurological consequences if left untreated [2]. The PAH enzyme functions 
in liver as homo-tetramers to hydroxylate phenylalanine (Phe) into tyrosine and requires 
the co-factor tetrahydrobiopterin for catalysis [3]. Dietary phenylalanine (Phe) tolerance 
among PKU patients differs widely depending on the body’s ability to maintain Phe 
homeostasis, resulting in a clinical continuum of phenotypes ranging from chronic mild 
hyperphenylalaninemia to severe classical PKU.  
 
The Pahenu2/enu2 mouse model recapitulates classical PKU with toxic 
hyperphenylalaninemia that causes neurological damage if untreated, and due to this 
classical PKU phenotype, is the most utilized animal model for testing novel 
therapeutics. Elevated brain Phe impairs cognitive and behavioral performance, as well 
as proper monoamine neurotransmitter production [4]. Abundant stable, nonfunctional 
PAH protein that is recognized by anti-PAH antibodies is expressed in liver [5]. For 
research that aims to perform preclinical gene therapy studies, the presence of this 
mutant protein introduces confounding variables and challenges to experimental design, 
analysis, and interpretation. These challenges include the inability to distinguish 
transgene-derived functional enzyme from native mutant PAH by 
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immunohistochemistry, as well as the dominant negative effect of mutant monomers 
forming hetero-tetramers with functional monomers, thereby lowering the overall activity 
of the holoenzyme complex [6]. In order to better evaluate genetic therapeutic 
interventions, a model that is completely void of PAH protein and activity is greatly 
desired. To accomplish this task, this study sought to delete the entire first exon of the 



















2. Materials & Methods 
2.1 Experimental Design 
2.1.1 Guide Design and Validation 
Single guide RNAs (sgRNA) were designed using the online guide design tools 
CHOPCHOP and MIT Guide Design, using nucleotides 87521818-87522107 of the 
murine GRCm38.p4 C57BL/6J chromosome 10 sequence, which contains the 5’ 
untranslated region (5’ UTR) through intervening sequence 1 (IVS 1) of the Pah locus. 
Of eight guides produced (Figure 1A), six were selected for further sgRNA investigation 
(guides 1,3,4,6,7,8). All guides were tested with the Takara Guide-It sgRNA In-Vitro 
Transcription Kit (Cat. No. 632635) and Screening System (Cat. No. 632639). Guides 3, 
4, 6, 7 and 8 proved effective at inducing a targeted double-stranded break in the PCR 
substrate, and only guide 1 was unable to induce a cut in the target DNA (Figure 1B). 
The sgRNAs 4 and 8, located in the 5’ UTR and IVS1, respectively, were selected for 
Pah gene targeting in murine embryos (Figure 1C).  
 
2.1.2 Delivery of Cas9/sgRNA to mouse zygotes  
Female C57BL/6N JAX® mice at 4-5 weeks of age were super-ovulated, mated with 
males, and 0.5 day old single cell zygotes were isolated as previously described [8]. 
Two approaches to accomplish mouse Pah exon 1 deletion were performed in this 
study. In the first approach, a mixture of Cas9 mRNA and sgRNAs were injected into 
the cytoplasm of the one-cell fertilized eggs [9]. In the second approach, electroporation 
of Cas9 protein/sgRNA (RNP) complex using the NEPA21 system (NEPA GENE Co. 
Ltd, Chiba Japan) was performed on single-cell fertilized eggs [10]. Zygotes from either 
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approach were then transferred into the oviducts of pseudo pregnant recipient CD1/NCrl 
foster dams (Charles River), and the surviving offspring were screened for sizable 
deletions in the Pah exon 1 region after weaning. 
 
2.1.3 PCR Screen for Deleted Alleles 
Tail biopsies were acquired from F0 animals at three weeks of age and screened for 
visually discernable deletions of 200 bp or more using standard PCR and gel 
electrophoresis. Forward primer 5’-GGTTGCGGAGAATCCATAC-3’ and reverse primer 
5’-TGACTAAGGACCAGCCATTTC-3’ which are complementary to Pah sequences 
outside the putative Cas9 cleavage sites were used to amplify 753 bp spanning the 5’ 
UTR and 3’ IVS1 of exon 1 in the Pah locus using standard PCR with Invitrogen 
PlatinumTM Taq DNA polymerase and the following cycling parameters: initial 
denaturation at 94°C for 5 minutes, followed with 30 cycles of denaturation at 94°C for 
30 seconds, primer annealing at 55°C for 30 seconds, and extension at 72°C for 1 
minute, and a final extension of 72°C for 5 minutes. Products were analyzed by 
electrophoresis on a 1% agarose gel with 1kb NEB ladder (Figure 1D and 1E). Bands 
approximately 500 bp in size were excised from the gel and purified with the Qiagen 
QIAQuick Gel Extraction kit (Cat. 28706X40) for Sanger sequencing. 
 
2.1.4 Knockout-allele Sanger Sequencing 
Purified approximately 500 bp PCR products described above were quantified using the 
Epoch Microplate Spectrophotometer and analyzed by standard Sanger sequencing 
with 5’-GGTTGCGGAGAATCCATAC-3’ forward primer on an ABI 3130XL sequencer. 
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2.2 Animal studies 
2.2.1 Animal husbandry 
Animal care and experimentation were performed in accordance with the guidelines of 
the Dept. of Comparative Medicine, Oregon Health & Science University and the 
National Institutes of Health Guide for the Care and Use of Laboratory animals. The 
knockout PahDexon1/Dexon1 mice were produced through male Pah+/Dexon1 x female 
Pah+/Dexon1 as well as male PahDexon1/Dexon1 x female Pah+/Dexon1 crosses. Pups were toe 
clipped at two weeks for genotyping and identification purposes. All mice were fed tap 
water and standard mouse chow (LabDiet Picolab Rodent Diet 5LOD, St. Louis, MO) ad 
libitum providing approximately 24% protein and 1.04% L-phenylalanine by weight, 
except breeders that received high energy chow (LabDiet Rodent High Energy Diet 
5058, St. Louis, MO) approximately 22% protein and 0.99% L-phenylalanine. Given that 
adult mice consume approximately 5 g chow per day, daily L-phenylalanine intake is 
estimated to be approximately 50 mg per day. The animals were housed under a 
standard 12 hours on, 12 hours off light cycle. All surgical procedures were carried out 
with inhaled isoflurane general anesthesia to minimize pain and discomfort. 
 
2.2.2 Gene Therapy 
Three 6-8 week old PahDexon1/Dexon1 mice (two males and one female) were treated with 
recombinant liver tropic adeno-associated virus serotype 8 vector containing AAV 2 
genome (AAV2/8) that expressed the murine Pah cDNA from a strong Liver Specific 
Promoter (LSPmPAH) at doses of either 1 x 1010 vector genomes (vg) (1 male), 1 x 1011 
vg (1 female), or 1 x 1012 vg (1 male) per mouse via retroorbital injection. An additional 
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control female animal was administered 1 x 1012 vg of a similar viral vector containing an 
inactivating frameshift mutation in the transgene, denoted as AAV2/8 LSPmPAHfs. 
Blood was obtained prior to AAV injection for measurement of blood Phe concentration. 
Two weeks later animals were harvested for molecular analyses, including serum and 
brain amino acid analysis, hepatic PAH enzyme activity, liver PAH fluorescent-
immunohistochemistry, and quantitative PCR (qPCR) to determine vg copy number in 
total liver DNA. 
 
A similar gene therapy study was performed in the Pahenu2/enu2 mouse model. Two 
cohorts of six adult Pahenu2/enu2 animals (3 male and 3 female) were administered 1 x 
1011 vg or 1 x 1012  vg AAV2/8 LSPmPAH via retro-orbital injection. Blood was obtained 
prior to AAV injection for measurement of blood Phe concentration. Two weeks later 
animals were harvested for molecular analyses, including serum Phe concentration, 
hepatic PAH enzyme activity, and quantitative PCR (qPCR) to determine vg copy 
number in total liver DNA. 
 
2.2.3 Euthanasia and tissue harvest 
Animals were sedated using inhaled isoflurane anesthesia. Whole blood was collected 
by cardiac puncture, allowed to clot in an Eppendorf tube, and serum was separated by 
centrifugation. The mice were then euthanized by exsanguination and perfused with 20 




2.3 Molecular Characterization 
2.3.1 Blood and Brain Amino Acids 
Blood and brain amino acid concentrations were determined using an established 
protocol [4] by pre-column derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl 
carbamate (AQC, Waters AccQ Tag™derivitization system) and separation by ultrahigh 
performance liquid chromatography and UV absorbance detection (Waters Acquity™ 
UPLC, Milford, MA) using the Waters Masstrak Amino Acid Analysis method (Figure 2B 
and 2C). 
 
2.3.2 Brain Neurotransmitters 
Mouse half brains were processed as previously described [4, 11] for the measurement 
of dopamine, homovanillic acid (HVA), 5-hydroxytryptophan (5-HTP), serotonin, and 5-
hydroxyindoleacetic acid (5-HIAA) through ultrahigh performance liquid chromatography 
(UHPLC) and electrochemical detection basically as previously established [12]. 
Neurotransmitter concentrations were corrected for the total protein content of brain 
homogenate and reported as nmol/g protein (Figure 2D, 2E, 2F and 2G). 
 
2.3.3 Liver PAH Enzyme Activity 
PAH enzyme activity was determined in liver homogenates using a radiometric 
chromatography assay [13] with modifications [14], corrected for protein content, and 




2.3.4 Liver PAH Western Blot 
Bulk liver homogenates were prepared by mechanical homogenization of four 10 mg 
biopsies in 800 µL of cold lysis buffer, followed by centrifugation at 770 rpm for 8 
minutes at 4°C. The supernatant was collected and quantified for protein concentration 
using the Micro BCA™ Protein Assay Kit from ThermoFisher (Cat. 23235).   Each lane 
was loaded with a sample preparation containing  250 ng of protein in 1 µL, NuPage 
LDS Sample Buffer, 50 mM dithiothreitol, and water up to a total volume of 10 µL and 
incubated at 70° C for 10 min. 3 µL of Magic Mark™ ladder and 10 µL of each sample 
were loaded on a NuPage pre-cast gel and separated by electrophoresis in MOPS 
buffer at 200V for 50 minutes. The protein was transferred to a polyvinylidene fluoride 
membrane with electrophoresis in NuPage transfer buffer at 100V for 45 minutes. The 
membrane was blocked with 5% milk in TBS-T (Tris Buffer Saline-Tween) and probed 
with rabbit polyclonal anti-PAH antibody (1:200 dilution, BS3704 PAH (R400) from 
Bioworld, Inc.) and GAPDH loading control antibody (1:200 dilution, MA5-15738 
GAPDH loading control antibody from Invitrogen) overnight. The membrane was 
washed with TBS-T and probed with HRP-conjugated goat anti-rabbit IgG secondary 
antibody (1:1000 dilution, A27034 Goat anti-rabbit IgG (H+L) from Thermo Scientific and 
m-IgG𝜅 BP-HRP Sc 506102 from Santa Cruz Biotechnology) for one hour and washed. 
Bands were visualized using enhanced chemiluminescence (Chemiluminescent 
Western Blot Detection from ThermoScientific) captured on the Azure Sapphire 




2.3.5 Quantitative PCR for Vector Genome Copy Number in Total Liver DNA 
Total liver genomic DNA from untreated PahDexon1/Dexon1 mice was spiked with linearized 
LSPmPAH vector DNA and then sequentially diluted to produce a series of qPCR 
standards with final concentrations of 0.1 vector genome/diploid liver genome (vg/dg), 1 
vg/dg, 3 vg/dg, 10 vg/dg, 30 vg/dg, 100 vg/dg, or 300 vg/dg. Total liver DNA isolated 
from gene therapy treated animals (three AAV2/8 LSPmPAH animals and one AAV2/8 
LSPmPAHfs animal), as well as an untreated PahDexon1/Dexon1 animal as a negative 
control, were subjected to qPCR, along with the standard series, using SYBR Select 
MM (Applied Biosystems), forward primer PAH7.125F, and reverse primer PAH10.12R, 
to produce fluorescently labeled PCR products. Amplification was carried out and 
analyzed on a Qiagen Rotor-Gene Q real-time thermocycler. The number of AAV vg/dg 
from gene therapy treated mice was then estimated by comparing the Ct values from 
the unknowns to a linear regression curve of Ct vs. vg/dg generated from the standard 
series (Table 1). Each standard sample was amplified in duplicate to generate the 
standard curve, while each unknown was amplified in triplicate with the mean vg/dg 
reported in Table 1. 
 
 
2.3.6 Liver PAH Fluorescent Immunohistochemistry 
Select animals of Pah+/+  and PahDexon1/Dexon1 genotype, as well as gene therapy treated 
PahDexon1/Dexon1 animals, underwent saline-paraformaldehyde perfusion in preparation for 
liver fixation and immunohistochemistry (Figure 3C and Figure 4). Under deep 
isoflurane inhaled anesthesia, mice were perfused with 0.9% saline via cardiac infusion 
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to clear the hepatic circulation of blood. Excised biopsies from each liver lobule were 
then fixed for 24 hours in fixation solution (4% paraformaldehyde in phosphate buffered 
saline) followed by immersion in 25% buffered sucrose for an additional 24 hours. 
Tissues were embedded in optimal cutting temperature media, sliced into 15 
micrometer sections, and mounted on glass slides. Sections were treated (following 
blocking) with rabbit polyclonal anti-PAH antibody (1:200 dilution, BS3704 PAH (R400) 
from Bioworld, Inc.) and incubated for 2 hours at room temperature. After appropriate 
washes, sections were treated with Alexa 488-conjugated goat anti-rabbit IgG 
secondary antibody (1:150 dilution, A11008 Alexa Fluor 488 goat anti-rabbit IgG (H+L) 
from Invitrogen) and incubated for one hour at room temperature. After washing, cover 
slips were mounted with Vectashield mounting medium containing DAPI. Images were 
captured on a Nikon H550L fluorescence microscope. 
 
2.3.7 PCR amplification and Sanger sequencing of potential CRISPR/Cas9 off 
target mutation sites 
Possible sites of off-target sgRNA-Cas9 genotoxicity were selected for Sanger 
sequencing analysis using the in silico COSMID tool [15], which used the guide 4 and 
guide 8 target sequence to determine the top four off-target sites in the mouse 
reference genome (GRCm38) for each guide. Sanger sequencing was performed for 
each region with location, off-target sequence, COSMID score (where lower score 
indicates higher likelihood of sgRNA-Cas9 double strand break lesions) and Sanger 
sequencing chromatogram displayed in Supplemental Figure 1. 
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3. Results  
3.1 Experimental Design 
3.1.1 Guide Validation 
Using two in silico single guide RNA (sgRNA) design tools, CHOPCHOP and MIT Guide 
Design, Streptococcus pyogenes Cas9 appropriate guides throughout the Pah 5’ 
upstream untranslated region (5’ UTR), exon 1, and intron 1 (IVS1) were identified 
(Figure 1A). Six sgRNAs (labeled guides 1, 3, 4, 6, 7 & 8) were selected to test for 
effective targeted double-stranded DNA breaks (DSB) (Figure 1A). Using the Takara In 
Vitro Guide-It assay, sgRNAs 3, 4, 6, 7 & 8 were identified as being effective at inducing 
a DSB in mouse DNA, provided the remaining necessary gene editing components, in 
an in vitro setting (Figure 1B). Guide 4 (5’ UTR) and guide 8 (IVS 1) were selected to 
knockout exon 1 of the Pah gene in murine embryos (Figure 1C). After CRISPR/Cas9-
mediated Pah gene targeting, the zygotes were transferred into oviducts of pseudo-
pregnant females yielding eighty-five liveborn F0 progeny.  
 
3.1.2 Pah exon1 Deletion Screen 
DNA isolated from tail biopsies of 85 potentially genetically altered offspring were 
analyzed for large deletions. PCR amplification of a 753 bp fragment flanking exon 1 in 
the Pah locus was performed, followed by gel electrophoresis, and screening for the 
presence of visually discernable deletions spanning approximately 200 bp or more 
(Figure 1D). CRISPR-modified alleles that contained small indels not visually detectable 
or large deletions greater in span than the amplicon and that would therefore not be 
amplified with this screening procedure were not further sought. Apparent heterozygous 
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Pah exon 1 deletions were detected in four female pups using this screening procedure, 
but only two could be confirmed and analyzed upon Sanger sequencing. The first 
animal carried a 243 bp deletion that was designated as allele a (Figure 1C). 
Unfortunately, this deleted allele was unable to be propagated through breeding and 
therefore was not further characterized. Fortunately, a 258 bp deletion spanning exon 1 
in a second founder animal, confirmed with Sanger sequencing and designated as allele 
b, was successfully propagated to an F1 generation and bred to homozygosity (Figure 
1C, 1D, 1E and 1F). Hereafter, we designate this mutant allele PahDexon1, and mice that 
are homozygous for this deleted allele as PahDexon1/Dexon1, heterozygous as Pah+/Dexon1 , 
and wild type as Pah+/+.  
 
3.2 Characterization of PahDexon1/Dexon1 animals 
3.2.1 Breeding of C57BL/6-PahDexon1/Dexon1 Mice 
Four Pah+/Dexon1 X  Pah+/Dexon1 crosses generated 23 pups with the following genotypes 
obtained at two weeks of life: 6  Pah+/+, 12 Pah+/Dexon1, and 5 PahDexon1/Dexon1. This yield 
of genotypes is consistent with the 1:2:1 ratio expected from Mendelian inheritance of a 
recessive trait (Chi square = 0.36, df=2, between the probability of 0.9 - 0.1, and thus 
the null hypothesis that there is no difference between the observed and expected ratios 
was not rejected). This result indicates that homozygosity for the PahDexon1 allele is not 
associated with embryonic or neonatal lethality. However, beyond 2 weeks age, we 
have observed spontaneous demise in 10/17 of PahDexon1/Dexon1 animals during the 
transition from nursing to dependence upon solid food. PahDexon1/Dexon1 mice that survive 
beyond weaning exhibit coat color hypopigmentation on an unrestricted diet (Figure 2A), 
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a characteristic phenotype of mouse models of PKU that results from phenylalanine-
mediated competitive inhibition of the melanin-synthesizing enzyme tyrosinase [16].    
 
3.2.2 Serum and brain amino acid profiles  
Serum and brain amino acid profiles were examined in adult (6-12 week old) 
PahDexon1/Dexon1 (N=6, 1 male and 5 female), Pah+/Dexon1 (N=3, 1 male and 2 female), and 
Pah+/+ (N=3, 1 male and 2 female) animals (Figure 2B). Serum phenylalanine levels in 
PahDexon1/Dexon1 mice averaged 2172 ± 275 µM (mean ± SD), consistent with severe 
PKU, and were significantly elevated in comparison to either Pah+/Dexon1 (80 ± 14 µM) or 
Pah+/+  (78 ± 12 µM) mice by one-way ANOVA (F (2,9)= 156.7, P < 0.0001). There was 
no difference of hyperphenylalaninemia between male and female PahDexon1/Dexon1 
animals in an unpaired t-test, with an average of 2364 µM in 3 male mice and 2248 µM 
in 7 female mice (p-value 0.7035). Serum tyrosine concentration was statistically 
different between genotypes by one-way ANOVA (F (2, 9) = 6.090, P =0.0213) with 
PahDexon1/Dexon1 (49 ± 13 µM) less than Pah+/+ animals (75 ± 10 µM) but not significantly 
different from Pah+/Dexon1 (62 ± 5 µM). 
 
Brain homogenates were analyzed for Phe, as well as the amino acid neurotransmitter 
precursors for dopamine and serotonin, tyrosine and tryptophan, respectively (Figure 
2C). Brain Phe content was statistically elevated in PahDexon1/Dexon1 mice (817 ± 90 
nmol/g) in comparison to either Pah+/Dexon1 (146 ± 19 nmol/g) or Pah+/+ animals (114 ± 9 
nmol/g) in a one-way ANOVA (F(2, 9) = 154.2, P < 0.0001). There were no statistical 
differences in brain tyrosine or tryptophan between the PahDexon1 allele genotypes 
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(Figure 2C), with brain Tyr of 90 ± 14 nmol/g and brain Trp of 26 ± 4 nmol/g in 
PahDexon1/Dexon1 animals. These data are similar to published brain large neutral amino 
acid profiles in Pahenu2/enu2 mice (brain Phe 762 ± 17 nmol/g, brain Tyr 85 ± 15 nmol/g, 
and brain Trp 20 ± 3 nmol/g) [4].  
 
3.2.3 Brain Neurotransmitters 
The content of the monoamine neurotransmitters dopamine, 5-hydroxytryptophan (5-
HTP), serotonin, and their metabolites homovanillic acid (HVA) and 5-
hydroxyindoleacetic acid (5-HIAA) were examined in adult PahDexon1 animals. There are 
two parallel pathways that lead to the synthesis and metabolism of dopamine and 
serotonin. In dopaminergic neurons, tyrosine hydroxylase converts tyrosine into L-
DOPA, which can then be converted into dopamine by L-amino acid decarboxylase (L-
AAAD). After dopamine is secreted into the synapse, it can either be taken up by 
dopamine specific transporter (DAT) or metabolized into HVA. In PahDexon1 animals, 
there was no difference in brain dopamine between PahDexon1/Dexon1 animals (196.8 ± 
38.78 nmol/g protein), Pah+/Dexon1 animals (260.6 ± 102.4 nmol/g) and Pah+/+ animals 
(234.3 ± 24.13 nmol/g protein) by one-way ANOVA (F (2,8) = 1.129, P = 0.3700), 
(Figure 2D). Interestingly, there was an significant difference in brain HVA among the 
groups (F (2,8) = 9.349, P = 0.0081), but post hoc intergroup comparison revealed only 
an unexplained significant increase (P = 0.016) in brain HVA of Pah+/Dexon1 animals 
(28.51 ± 3.74 nmol/ g protein) in comparison to Pah+/+ animals (19.04 ± 2.03 nmol/g) but 
no significant difference (P = 0.9453) between PahDexon1/Dexon1 animals (18.36 ± 3.73 
nmol/g) and wild type mice (Figure 2E).  
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In the serotonergic neurons, tryptophan hydroxylase converts tryptophan into 5-HTP, 
which can then be converted by L-AAAD into serotonin. After serotonin is secreted into 
the synapse, it can either be taken up by serotonin reuptake transporters or metabolized 
into 5-HIAA. In contrast to dopamine, the brain serotonin content was significantly 
different among Pah+/+, Pah+/Dexon1, PahDexon1/Dexon1 mice (one-way ANOVA F (2,8) = 
91.20, P < 0.0001), (Figure 2F). Brain serotonin content was significantly lower (p = 
0.0001) in PahDexon1/Dexon1 animals (47.30 ± 5.79 nmol/g protein) than in wild type 
animals (90.53 ±3.10 nmol/g). Inexplicably, brain serotonin was somewhat increased (P 
= 0.002) in Pah+/Dexon1 mice (122.1 ± 12.8 nmol/g) although we analyzed only 3 mice in 
this group.  Similarly, the brain content of 5-HIAA, a marker of serotonin turnover, was 
significantly different among the genotypes by one-way ANOVA (F (2, 8) = 22.42, P = 
0.0005), (Figure 2G). Brain 5-HIAA was significantly decreased (P = 0.0048) in 
PahDexon1/Dexon1 animals (18.95 ± 6.28 nmol/g protein) in comparison to Pah+/+ animals 
(73.60 ± 10.11 nmol/ g protein). Brain 5-HIAA content was not significantly different (P = 
0.1629) between wild type and Pah+/Dexon1 animals (100.3 ± 32.24 nmol/g protein).  
 
3.2.4 PAH Enzyme Activity 
Liver PAH enzymatic activity was measured in homogenates from PahDexon1/Dexon1 and 
Pah+/Dexon1 mice and compared to that of the existing PKU model, Pahenu2/enu2 along with 
Pah+/enu2 mice (Figure 3A). Liver PAH enzyme activity is expressed as the percent of 
wild type C57BL/6 liver activity. As expected, PAH activity was undetectable in liver of 
either PahDexon1/Dexon1 or Pahenu2/enu2 mice. However, there was a surprising difference in 
the liver PAH activity measured in heterozygous Pah+/Dexon1 (58 ± 7% wild type activity) 
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and Pah+/enu2 (29 ± 5% wild type activity) mice, with a P < 0.0001 via post-hoc intergroup 
comparison analysis with Tukey multiple comparisons test (Figure 3A).  
 
3.2.5 PAH Protein Expression 
Western blot analysis of bulk liver homogenate revealed no visible band for anti-PAH 
staining at the expected 50 kDa size in PahDexon1/Dexon1 animals (Figure 3B). There is a 
strong band for PAH in Pah+/+ animals, and less intense but visible PAH bands in 
Pah+/Dexon1 and Pahenu2/enu2 animals. Bands staining for GAPDH at 37 kDa reveal similar 
protein loading in all samples. 
 
Liver fluorescent-immunohistochemistry using anti-PAH antibody conjugated to Alexa 
Fluor 488 (green) and nuclear staining with DAPI (blue), revealed strong PAH 
expression in Pah+/+ mice but complete absence of visible PAH expression in 
PahDexon1/Dexon1 animals (Figure 3C). 
 
3.2.6 PCR amplification and Sanger sequencing of potential CRISPR/Cas9 off 
target mutation sites 
PCR amplification and Sanger sequencing of the top four predicted off target sites for 
Cas9-mediated double strand breaks associated with each of the guide RNA sequences 
used to produce the Pah exon 1 deletion detected no deleterious sequence differences 




3.3 Gene Addition Therapy in PahDexon1/Dexon1 animals 
3.3.1 Gene Therapy 
In order to demonstrate applicability of this model, liver tropic recombinant adeno-
associated virus serotype 8 (rAAV8) containing the murine Pah (mPAH) cDNA (rAAV2/8 
LSPmPAH) [17] was administered to three homozygous PahDexon1 animals in a small 
preliminary dose escalation experiment. The highest, middle, and lowest doses (1 X 
1012 vector genomes (vg), 1 X 1011 vg, and 1 X 1010 vg of rAAV2/8 LSPmPAH, 
respectively) were delivered systemically via retro-orbital injection. A control animal 
received rAAV2/8 vector containing a nonsense frameshift mutation that abolishes PAH 
expression (1 X 1012 vg rAAV2/8 LSPmPAHfs). The phenylalanine levels in the three 
treated animals showed substantial correction in blood (127 µM, 194 µM, and 235 µM, 
respectively) and brain (382 nmol/g, 135 nmol/g, and 325 nmol/g, respectively) 14 days 
post-administration at all three vector doses while the animal that received the 
frameshift virus maintained elevated blood (1,928 µM) and brain (1,222 nmol/g) Phe 
levels (Table 1). Interestingly, the gene therapy treated animals exhibited liver PAH 
enzyme activity (96.1%, 42.0%, and 4.8% of wild type C57BL/6 liver activity), rAAV2 
vector genome copy number (49.7 ± 2.9 vg, 16.2 ± 3.1 vg, and 2.9 ± 0.2 vg/ diploid liver 
genome), and intensity of liver fluorescent-immunohistochemical PAH staining that 
correlated with the vector dose (Table 1 and Figure 4).  
 
Similar gene addition therapy was administered to Pahenu2/enu2 animals (3 males and 3 
females per dose) systemically through the retro-orbital route with doses of 1 x 1011 vg 
and 1 x 1012 vg of rAAV2/8 LSPmPAH, that conferred reduced Phe of 176 ± 52 µM and 
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99 ± 22 µM, respectively, % WT PAH enzyme activity of 7.7 ± 2.2% and 14.8 ± 3.3%, 























4. Discussion  
This study was able to successfully generate a novel murine model for classical PKU 
completely void of hepatic PAH protein expression. Pah+/Dexon1 x Pah+/Dexon1 mating 
produced the expected 1:2:1 Mendelian ratios of Pah+/+ to Pah+/Dexon1 to PahDexon1/Dexon1 
offspring. Additionally, female Pah+/Dexon1 x male PahDexon1/Dexon1 mating was productive, 
yielding progeny in a 1:1 ratio of Pah+/Dexon1 to PahDexon1/Dexon1 animals. Complete PAH 
deficiency did not cause embryonic or neonatal lethality. However, PahDexon1/Dexon1 mice 
struggled to wean from nursing to solid food more frequently than the prior existing 
Pahenu2/enu2 model, with increased mortality at weaning. They required more attention to 
husbandry at this period with delayed separation from their dam and provision of soft 
food placed directly in the bottom of the cage until they demonstrated consistent ability 
to reach the chow overhead in the cage lid. The precise reason for this difference in the 
phenotype at weaning between the PahDexon1/Dexon1 and Pahenu2/enu2 models requires 
further investigation. There were no other obvious differences in the physical phenotype 
or neurologic performance of the two models to explain the loss of PahDexon1/Dexon1 mice 
near weaning. Blood and brain amino acid concentrations including the levels of 
phenylalanine and tyrosine in adult mice that survived weaning did not differ significantly 
between the two mouse strains, with the exception that the effect of sex upon serum 
Phe seen in Pahenu2/enu2 mice (higher mean blood Phe in females than in males) was not 
demonstrated in PahDexon1/Dexon1 mice. Brain neurotransmitter evaluation in 
PahDexon1/Dexon1 mice revealed findings analogous to those previously reported in the 
Pahenu2/enu2 model, which showed minimal disruptions in the dopamine pathway, but 
significant deficiencies in serotonin production [4]. The main biochemical difference 
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between the PahDexon1/Dexon1 and Pahenu2/enu2 models is the complete lack of detectable 
PAH protein in the knockout mouse. Deleterious CRISPR/Cas9-mediated mutation at 
an off-target site is a theoretical, low probability event that could adversely affect the 
phenotype of PahDexon1/Dexon1 mice. PCR amplification and Sanger sequencing of the top 
four predicted off-target Cas9 cutting sites for each the two guides used to develop the 
mouse detected no genotoxicity at any of those eight locations, however this approach 
was not comprehensive for the entire genome. To eliminate the possibility of any 
adverse mutations at alleles other than Pah, we are currently outbreeding the PahDexon1 
allele onto a clean C57BL/6 genetic background.  
 
Prior to this, the available mammalian animal models of PKU consisted of mouse 
models denoted as Pahenu1/enu1, Pahenu2/enu2, and Pahenu3/enu3, which were created by 
random N-ethyl-N-nitrosourea (ENU) mutagenesis [5]. The Pahenu3 allele, which is no 
longer available due to breeding difficulties and neonatal fatality, contained a frameshift 
mutation that caused premature termination of the tetramerization domain [18].  Pahenu1 
and Pahenu2 alleles are missense mutations that result in phenotypes on opposite ends 
of the hyperphenylalaninemia spectrum and are the predominant models of PKU to 
date. An additional model of PKU combines enu1 and enu2 as a heteroallelic 
Pahenu1/enu2 model, recapitulating compound heterozygosity for PAH mutations which 
occurs in approximately 87% of humans with PKU [19, 20]. The Pahenu1/enu1 and 
Pahenu1/enu2 models are less desirable for gene and cell interventions due to their mild 
phenotype.      
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The longstanding and most popular mouse model for preclinical PKU gene therapy 
studies has been the Pahenu2/enu2 model, which is homozygous for a p.F263S (c.835 
T>C) missense mutation in the central catalytic domain of PAH. It produces abundant 
albeit inactive PAH enzyme and recapitulates classical human PKU, with severe 
hyperphenylalaninemia, cognitive and behavioral disabilities, hypopigmentation, and 
occasional seizures. We and other groups have successfully treated adult Pahenu2/enu2 
animals with AAV-mediated gene addition therapy demonstrating robust, long-term 
efficacy [17, 21-23]. Additionally, this model has been used in hepatocyte transplant 
studies [24-26] and CRISPR/Cas9-mediated gene correction of the enu2 point mutation 
in neonatal [27] and adult animals [28]. While these studies have driven the 
advancements in PKU therapeutic development, there is a significant limitation in this 
model, specifically the expression of inactive PAH monomer, leading to barriers in both 
efficacy and molecular analyses of gene and cell therapeutic interventions. The 
expression of mutant PAH protein makes immuno-based molecular analyses using anti-
PAH antibodies following gene therapy uninformative as the ability to quantify or localize 
transgene-delivered protein is limited. Additionally, it has been proposed that the native 
mutant PAH monomers interact with and reduce overall activity of wild type monomers, 
and in this mouse model, pose an additional barrier to efficacy in gene therapy studies.  
 
The possibility that mutant PAH monomers might have a dominant negative effect upon 
the activity of wild type PAH was first suggested from a study of liver PAH activities 
measured in parents of children with PKU [29]. In these individuals who were 
presumably heterozygous for pathogenic PAH mutations (the study occurred prior to 
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cloning of the PAH gene), liver PAH activity measured only 4.4-23% of wild type activity 
rather than the 50% typically expected for a recessively-inherited disorder. In this new 
study, we now confirm significant differences in liver PAH enzyme activity between 
Pah+/Dexon1 and Pah+/enu2  heterozygous animals, indicating that the production of mutant 
F263S monomers in Pah+/enu2  heterozygous mice adversely impacted the proper 
function of wild type PAH. These data provide strong in vivo evidence for the dominant 
negative effect of at least this single missense Pah mutation. Further studies are 
warranted to confirm these findings and extend them to the Pahenu1 model. We propose 
that this phenomenon may extend to multiple human missense PAH mutations.  
 
Preliminary results from a small liver-directed AAV8-mediated dose escalation gene 
addition trial in three PahDexon1/Dexon1 mice revealed the utility of this model for liver gene 
transfer studies particularly in regard to employing anti-PAH immunohistochemistry in 
the assessment of hepatocyte transduction frequency, a feat that was previously 
unachievable in existing murine models. Furthermore, comparison of the efficacy in this 
small trial to the efficacy of Pahenu2/enu2 mice corroborates the suspicion that F263S 
mutant monomers present in the latter model inhibit the activity of wild type transgene-
produced PAH and thereby limit treatment efficacy.  Despite similar vector genome 
numbers within hepatocytes of the PahDexon1/Dexon1 and Pahenu2/enu2  animals, PAH 
enzyme activity was far greater in the PahDexon1/Dexon1 animals (Figure 3A). More 
PahDexon1/Dexon1 animals need to be treated to confirm these findings, but nevertheless 
we are confident in reporting that this knockout model is more sensitive to therapeutic 
intervention and is better able to depict a more accurate analysis of vector genome to 
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PAH activity due to the lack of mutant monomer expression, ameliorating the dominant 
negative effect observed in Pahenu2/enu2  mice.  
In conclusion, we report the development of a novel PAH deficient murine model 
harboring a recessively inherited deletion of Pah exon 1. Because anti-PAH 
immunohistochemistry can be readily employed to track hepatocyte transduction 
following gene therapy, in addition to an apparently improved therapeutic threshold in 
comparison to the existing Pahenu2 model, we predict that this novel model will find 
particular utility in the future investigation of gene addition and gene editing methods. 
Importantly, with AAV-mediated gene addition therapy for PKU now entering human 
trials, this model provides a platform to more clearly correlate gene therapy treatment 
with physiological outcomes and aid our understanding of clinical trial results. While 
creating a model for classical PKU gene therapy with fewer confounding variables and 
enhanced molecular analyses was the impetus for this project, the overarching goal of 
generating this model was to add to the experimental tools available for PKU scientists 











Figure 1: Experimental Design, Screening, and Sequencing.  
A. In silico Guide Generation. The table displays the six guides that were selected for 
in vitro analysis using the MIT Guide Design in silico tool. Guide ID, Target Sequence, 
PAM site, Strand (plus or minus), and MIT Score are displayed, where higher scores 
indicate an improved prediction for cutting efficiency. B. In vitro Guide Validation. Gel 
electrophoresis of in vitro Guide-It Takara Assay performed with the six guides identified 
in Supplemental 1A and run on a 3% agarose gel. In the left gel, Guide1 displays no 
cutting of substrate, while guides 7 and 8 display partial cutting of substrate into 300 bp 
and 500 bp bands and 200 bp and 600 bp bands, respectively. In the right gel, Guides 
3, 4, and 6 show complete cutting of substrate, with a doublet of 400 bp bands from 
guide 3 cutting, 300 bp and 500 bp from guide 4, and 350 bp and 450 bp from guide 6. 
Of note, guide 1, the only guide that did not demonstrate substrate cutting. C. Pah exon 
1 knockout design. The diagram illustrates the experimental design to use 
CRISPR/Cas9 mediated technology with strategically selected sgRNAs to knockout 
exon 1 of the Pah locus. The gene structure of murine Pah, located on chromosome 10, 
is shown with exon 1, exon 2, exon 12, and exon 13 labeled, and // indicates the gene 
structure containing exons 3-11. Locations of Guide 4 (5’ UTR) and Guide 8 (exon1-
IVS1 junction) are displayed and placed below the Pah structure due to targeting of the 
minus strand DNA sequence. The PCR design to detect large, 200+ bp deletions in the 
5’ Pah locus is indicated with black arrows to represent primers. Forward primer is 
located in the 5’ UTR and 3’ primer is located in IVS1 (where // indicates DNA gap), 
resulting in amplification a 753 bp product that flanks exon 1 in the absence of gene 
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modification. Two founder females were identified with deletions spanning exon 1; one 
animal contained a deletion of 243 bp, designated allele a, and the other animal 
contained a deletion of 258 bp, designated allele b. D. Gel electrophoresis of F0 
Pah+/Dexon1 female mouse. Tail biopsy DNA from potential Pah+/Dexon1 founder mice was 
amplified with the primers described in Figure 1C. All mice have expected the expected 
wild type  ~750 bp band but founder b (693) carries an additional ~500 bp band 
representing an allele with a ~250 bp deletion. E. Gel electrophoresis of F2 PahDexon1 
allele progeny.  Genotyping of the progeny form a Pah+/Dexon1 X Pah+/Dexon1 breeding: 
Mouse 37 (Pah+/Dexon1), Mouse 38 (PahDexon1/Dexon1), Mouse 39 (Pah+/+), Mouse 40 
(PahDexon1/Dexon1), Mouse 41 (Pah+/Dexon1), and Mouse 42 (Pah+/Dexon1). Pah+/+ contains a 
single ~750 band, Pah+/Dexon1 contains two bands, a ~750 bp band and a ~500 bp band, 
and PahDexon1/Dexon1 contains a single ~500 bp band. E. Sanger Sequencing of 
PahDexon1 Allele. The chromatogram displays 12 nucleotides spanning in either direction 
from the deleted region in the PahDexon1 allele, indicated with the black triangle.  
 
Figure 2: Characterization Amino Acids & Derivatives in Pah△exon1 Mice 
A. Coat Pigmentation. Photograph of untreated PahDexon1/Dexon1 (left) and Pah+/Dexon1 
(right) mice on standard mouse chow diet. B. Serum Phe & Tyr. Mean serum 
phenylalanine and tyrosine concentration (± SD) of adult PahDexon1/Dexon1, Pah+/Dexon1, and 
Pah+/+ animals following euthanasia. The left y-axis indicates µM serum amino acid 
concentration. The average serum Phe was 2172 µM, 80 µM, and 78 µM, respectively. 
One-way ANOVA revealed significant effects of genotype on serum Phe (F (2,9)= 
156.7, P < 0.0001). The average serum Tyr was 49 µM, 62 µM, and 75 µM, 
 28 
respectively. One-way ANOVA revealed significant effects of genotype on serum Tyr  
between PahDexon1/Dexon1 and Pah+/+ animals (F (2, 9) = 6.090, P = 0.0213). C. Brain 
LNAAs. Mean brain LNAA concentrations (± SD) of PahDexon1/Dexon1, Pah+/Dexon1, and 
Pah+/+ animals at time of euthanasia. The y-axis indicates amino acid concentration in 
nmol/g wet weight. The average brain Phe was 817 nmol/g, 146 nmol/g, and 114 
nmol/g, respectively. One-way ANOVA revealed significant effects of genotype on brain 
Phe (F(2, 9) = 154.2, P < 0.0001). The average brain Tyr was 90 nmol/g, 105 nmol/g, 
and 100 nmol/g, respectively and brain Trp was 26 nmol/g, 32 nmol/g, 28 nmol/g, 
respectively. One-way ANOVA revealed no statistical differences in brain Tyr or Trp in 
PahDexon1 allele mice. D. Brain Dopamine. Brain dopamine concentrations in nmol/g 
protein (y-axis) of individual animals (represented as single points) in each genotype of 
PahDexon1 allele mice (x-axis). There was no statistical significance in brain dopamine 
across genotypes by one-way ANOVA (F (2,8) = 1.129, P = 0.3700). E. Brain HVA. 
Brain HVA concentrations in nmol/g protein (y-axis) of individual animals (represented 
as single points) in each genotype of PahDexon1 allele mice (x-axis). There was a 
significant difference in brain HVA across genotypes (one-way ANOVA F = [2, 8] = 
9.349, p = 0.0081) with post-hoc multiple comparisons showing a significant increase of 
HVA in heterozygous animals in comparison to WT animals (adjusted P = 0.016) but no 
difference between homozygous and WT animals (adjusted P = 0.9453). F. Brain 
Serotonin in PahDexon1 Allele Mice. Brain serotonin concentrations in nmol/g protein (y-
axis) of individual animals (represented as single points) in each genotype of PahDexon1 
allele mice (x-axis). There was a significant difference in brain serotonin across 
genotypes (one-way ANOVA (F [2,8] = 91.20, P < 0.0001), with significantly less brain 
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serotonin in PahDexon1/Dexon1 animals (47.30 nmol/g protein) than wild type (90.53 nmol/g 
protein) or heterozygous (122.1 nmol/g protein) animals. G. Brain 5-HIAA. Brain 5-
HIAA concentrations in nmol/g protein (y-axis) of individual animals (represented as 
single points) in each genotype of PahDexon1 allele mice (x-axis). There was a significant 
difference in brain 5-HIAA across genotypes (one-way ANOVA: F [2,8] = 22.42, p = 
0.0005), with less brain 5-HIAA in PahDexon1/Dexon1 animals (18.95 nmol/g protein) than 
wild type (73.6 nmol/g protein) or heterozygous (100.3 nmol/g protein) animals.  
 
Figure 3: Characterization of PAH in Pah△exon1 Mice 
A. Liver PAH Enzyme Activity. Mean liver PAH enzyme activity (± SD) in homozygous 
and heterozygous PahDexon1 and Pahenu2 mice. The y-axis indicates liver PAH activity 
expressed as percent wild type (WT) PAH enzyme activity. The average enzyme activity 
was 58% in Pah+/ Dexon and 29% in Pah+/enu2, while all homozygous recessive animals 
were 0%.  One-way ANOVA revealed statistical differences in percent WT PAH enzyme 
activity across these genotypes (F (3, 18) = 212.7, P < 0.0001). B. Liver PAH Western 
Blot. Western blot analysis of anti-PAH and anti-GAPDH in liver homogenates from 
PahDexon1 allele and Pahenu2/enu2 mice. The arrows on the left of the image indicate band 
sizes for PAH at 50kDa (top) and GAPDH at 37kDa (bottom). C. Liver PAH 
Fluorescent Immunohistochemistry. Anti-PAH fluorescent immunohistochemistry in 
liver tissue samples from Pah+/+ and PahDexon1/Dexon1 mice. Green indicates the presence 
of PAH by anti-PAH antibodies bound by secondary antibodies conjugated with 
AlexaFluor 488 (green fluorescence) and blue indicates nuclear staining with DAPI. The 
left image depicts PAH IHC on untreated Pah+/+ liver tissue with strong green signal and 
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top right image displays PAH IHC of untreated PahDexon1/Dexon1 liver tissue with absent 
green signal. 
 
Table 1: Molecular Analyses of Gene Therapy Treated Pah△exon1/△exon1 and 
Pahenu2/enu2 Mice. Pre- and post- gene therapy (GT) effects in a dose escalation 
experiment in PahDexon1/Dexon1 mice, as well as gene addition therapy in Pahenu2/enu2 
animals. The first column indicates the gene therapy administered, including dose and 
transgene, where rAAV2/8 LSPmPAH indicates a therapeutic virus containing an rAAV2 
genome with a transgene cassette containing a Liver Specific Promoter driving murine 
PAH packaged into an AAV8 capsid. The AAV2/8 LSPmPAHfs contains a frameshift 
and is used as a control vector.  
 
Figure 4: Liver PAH Fluorescent Immunohistochemistry of Gene Therapy Treated 
Pah△exon1/△exon1 Mice. Anti-PAH fluorescent-immunohistochemistry in liver tissue 
samples from gene addition therapy treated PahDexon1/Dexon1 mice. Green indicates the 
presence of PAH by anti-PAH antibodies bound by secondary antibodies conjugated 
with AlexaFluor 488 (green fluorescence) and blue indicates nuclear staining with DAPI. 
The four images display the gene therapy treated PahDexon1/Dexon1 mice as labelled 
according to dosing of therapeutic vectors of LSPmPAH AAV2/8: 1 X 1012 vg (top left 
image labelled with 1E12), 1 X 1011 vg (top right image labelled with 1E11 ), and 1 X 
1010 vg (bottom left image labelled with 1E10), followed by 1 X 1012  vg of the control 
vector (LSPmPAHfs) containing a frameshift (bottom right image labelled with 1e12fs).  
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Supplemental Figure 1: sgRNA Off-Target Sanger Sequencing 
A. Guide 4 Off-Target Sanger Sequencing. Guide 4 sequence with PAM site is 
displayed at the top, followed by chromatograms displaying the top four Guide 4 off-
target sites, including location, sequence (PAM site in red), and COSMID score. B. 
Guide 8 Off-Target Sanger Sequencing. Guide 8 sequence (with PAM site in red) is 
displayed at the top, followed by chromatograms displaying the top four Guide 8 off-
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A. In silico guide generation B. In vitro guide validation 
C. Pah exon 1 knock-out design
D. Gel electrophoresis of F0 Pah+/△exon1
Guide ID Target Sequence PAM Strand
MIT 
Score
Guide 1 TGTCTATCCACTGCTACGTC AGG Plus 90
Guide 3 CGGGGCTGATGGTTTTAACC TGG Minus 87
Guide 4 GTGTTGCCCTGACGTAGCAG TGG Minus 84
Guide 6 GTTAGGAAAAGTTTGCACTC AGG Minus 75
Guide 7 TGCTCAGGACTCCGTTCTCC AGG Minus 74
Guide 8 TTTGGGCAGGTAAGCCTGTT GGG Plus 73
1                2                            12             13 
Chr. 10
Pah locus
Richards et al. Figure 1: Experimental Design, Screening, and Sequencing
F. Pah△exon1 Sanger Sequencing
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Richards et al. Figure 3: Characterization of PAH in Pah△exon1 Mice
C. Liver PAH Fluorescent Immunohistochemistry
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ND – not done. a – mean ± SD. b - range
1E12 1E11
1E10 1E12fs
Richards et al. Figure 4: Liver PAH Fluorescent Immunohistochemistry of 
Gene Therapy Treated Pah△exon1/△exon1 Mice 














Chromatogram displaying complementary sequence:
A. Guide 4 Off-Target Sanger Sequencing
B. Guide 8 Off-Target Sanger Sequencing















Chromatogram displaying complementary sequence:
Richards et al. Supplemental Figure 1: sgRNA Off-Target Sanger Sequencing
